

Special Issue

Plasma Biomarkers for the Diagnosis and Prognosis of Cardiac Ischemic Events or Contractile Dysfunction

Message from the Guest Editor

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, with ischemic heart disease and myocardial contractile dysfunction representing major contributors of adverse clinical outcomes. Early detection, accurate risk stratification, and timely therapeutic intervention depend increasingly on the identification of reliable plasma biomarkers that reflect myocardial injury, ischemia, inflammation, fibrosis, metabolic stress, or impaired contractility. Despite the widespread use of established biomarkers such as cardiac troponins and natriuretic peptides, emerging molecular signatures, including microRNAs, extracellular vesicles, metabolomic and proteomic profiles, inflammatory mediators, and novel cardiac-specific proteins, are transforming the diagnostic and prognostic landscape. This Special Issue aims to gather cutting-edge research that will advance the understanding, validation, and clinical application of plasma biomarkers in the context of cardiac ischemia and myocardial dysfunction.

Guest Editor

Dr. Óscar Lorenzo González

School of Medicine, Universidad Autonoma de Madrid, 28049 Madrid, Spain

Deadline for manuscript submissions

30 September 2026



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.6
CiteScore 4.5
Indexed in PubMed



mdpi.com/si/274399

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.6
CiteScore 4.5
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience.

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q1 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 23.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2026).